Cardiology textbook flags India's central-obesity risk

A new cardiology textbook is released, foregrounding abdominal (visceral) obesity as an independent cardiometabolic risk in Indians — high even in lean-looking people.

What happened

• On 29 March 2026, the Minister of State (Independent Charge) for Science & Technology, Dr Jitendra Singh, released a textbook of cardiology titled "Advances in Obesity and Lipid Management in CVD" (CVD = cardiovascular disease).
• The Minister's central message: abdominal or central obesity is a greater risk factor than overall (general) obesity, particularly in the Indian context, where even lean and thin-looking individuals often carry significant visceral fat.
• He stressed that central obesity is a risk factor independent of obesity as such — it raises cardiometabolic risk even in people who are not classified as obese by body weight.
• Central obesity, he said, predisposes individuals to a spectrum of disorders: type-2 diabetes, hypertension, cardiovascular disease, fatty liver, and lipid disorders (dyslipidemia).
• The book, edited by cardiologist Dr H.K. Chopra, draws on more than 300 contributors from India and abroad, and is organised into 23 sections and 172 chapters.
• The Minister framed the release as aligned with the Prime Minister's call for public awareness, reduced edible-oil and unhealthy-food intake, and the goal of an "Obesity-Free Bharat".

Background & context

The release is not the launch of a scheme or a body; it is the publication of a specialist medical reference book whose headline claim is what carries exam weight — the idea of central (abdominal / visceral) obesity and the distinct Indian phenotype. Understanding why this is being flagged at the level of a Union Minister requires placing it in the longer arc of India's non-communicable-disease (NCD) burden.

Obesity is conventionally measured by Body Mass Index (BMI) — weight in kilograms divided by height in metres squared. By the World Health Organization's general cut-offs, a BMI of 25 and above is overweight and 30 and above is obese. The textbook's argument, voiced by the Minister, is that BMI alone understates the risk Indians carry, because the Indian body tends to store fat around the abdomen and viscera (the organs) rather than under the skin or in the limbs. This is the "thin-fat" or "thin-outside-fat-inside" (TOFI) pattern: a person of normal weight on the scale can still carry dangerous internal fat. For this reason, public-health guidance increasingly pairs BMI with waist circumference and the waist-to-hip ratio as measures of central adiposity. India's revised national obesity guidelines (2025) explicitly recommend lower BMI thresholds and abdominal-fat measurement for Indians, reflecting exactly this concern.

The book sits inside the government's stated health vision — "Viksit Bharat, Swasthya Bharat and Obesity-Free Bharat" — and follows the Prime Minister's repeated public appeals (including in his radio address) for citizens to cut edible-oil consumption by about a tenth and adopt lifestyle discipline. It is also a Science & Technology Ministry framing rather than a Health Ministry one, because the volume positions the response as a science-and-technology story: precision prevention, new drug classes, digital health and AI-enabled clinical decision tools, not merely diet advice.

Why the Indian phenotype is treated as distinct is itself worth grasping. Long-running epidemiological observation has noted that, at the same BMI, Indians and other South Asians tend to carry more body fat and more visceral fat than many Western populations, and develop diabetes and cardiovascular disease at lower body weights and younger ages. The mechanism the textbook leans on is metabolic: visceral fat is biologically active, releasing free fatty acids and inflammatory signals that drive insulin resistance — the state in which the body's cells respond poorly to insulin — which in turn links abdominal fat to type-2 diabetes, fatty liver and the lipid abnormalities that accelerate heart disease. This is why the volume threads obesity, lipids and cardiovascular disease together rather than treating them as separate specialities, and why it foregrounds prevention and early screening over late-stage cardiac intervention.

For Prelims

• The book: "Advances in Obesity and Lipid Management in CVD" · a textbook of cardiology · edited by Dr H.K. Chopra · 23 sections · 172 chapters · 300+ contributors from India and abroad.
• Released by: Dr Jitendra Singh, MoS (Independent Charge) for Science & Technology (also handling Earth Sciences, and MoS in PMO, Personnel, Department of Atomic Energy and Department of Space).
• Central / abdominal / visceral obesity: fat stored around the abdomen and internal organs; measured by waist circumference and waist-to-hip ratio, not by body weight or BMI alone.
• Core claim: central obesity is an independent cardiometabolic risk factor — it raises risk even in lean-looking, non-obese Indians (the "thin-fat" / TOFI phenotype).
• Diseases it predisposes to: type-2 diabetes, hypertension, cardiovascular disease, fatty liver (non-alcoholic fatty liver disease), insulin resistance, dyslipidemia and early-onset cardiac events — now seen in younger populations.
• GLP-1 receptor agonists (anti-obesity / anti-diabetic drug class): Semaglutide and Tirzepatide are the two named in the book. GLP-1 = glucagon-like peptide-1, a gut hormone that lowers blood sugar and appetite. (Tirzepatide is technically a dual GIP/GLP-1 agonist.)
• Lipid-lowering agents named: statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran, plus apheresis and gene-based interventions. These manage dyslipidemia — abnormal blood-lipid (cholesterol/triglyceride) levels.
• Framing shift: from conventional risk-factor-based management to "precision prevention", integrating metabolic therapies, lipid management, digital health and AI-enabled clinical decision systems.
• Policy umbrella: "Viksit Bharat, Swasthya Bharat and Obesity-Free Bharat"; linked to the PM's call for lower oil intake and lifestyle modification.
• What it is NOT: this is not a government scheme, mission or regulatory body — it is a privately edited medical textbook released at an official function; do not pair it with an outlay, a nodal agency, or a beneficiary count. Central obesity is also not the same as general (BMI-defined) obesity — that distinction is the whole point. GLP-1 agonists are not insulin and not statins; statins lower lipids, GLP-1 agonists act on appetite and blood sugar. NAFLD (fatty liver) here is the non-alcoholic type driven by metabolic fat, not alcohol-related liver disease.

The full comparative set — measures of body fat (for "how many / match the pairs" questions): BMI (weight ÷ height², general obesity) · Waist circumference (absolute abdominal fat) · Waist-to-hip ratio (fat distribution; central vs peripheral) · Waist-to-height ratio (an alternative central-fat screen) · Body-fat percentage (total adiposity). Central obesity is captured by the middle three, general obesity by BMI. The textbook's claim is that for Indians the central measures predict cardiometabolic disease better than BMI alone.

The drug-class set, to keep them straight: Statins (e.g. atorvastatin) block cholesterol synthesis · Ezetimibe blocks cholesterol absorption · Bempedoic acid acts upstream of statins in the same pathway · PCSK9 inhibitors (monoclonal antibodies) clear LDL from the blood · Inclisiran is a small-interfering-RNA (siRNA) agent that silences PCSK9 · GLP-1 receptor agonists (Semaglutide, Tirzepatide) are weight-and-sugar drugs, a different class from all the lipid agents above. Knowing that the first five are lipid-lowering and the last is anti-obesity/anti-diabetic is the survivable distinction.

Why it matters

The significance is epidemiological and policy-shaped. India faces a rising non-communicable-disease burden — cardiovascular disease and type-2 diabetes are leading causes of death and disability — and the release explicitly notes growing incidence of metabolic disorders, including type-2 diabetes and cardiac events, among younger populations. The Minister referred to projections of a sharp rise in obesity prevalence in India by 2050. The "thin-fat" insight matters because a screening system built only on BMI will miss a large share of at-risk Indians who look slim but carry visceral fat; flagging central obesity reframes who should be screened and how early. The book's emphasis on early screening, awareness and preventive care also aligns with the broader public-health push behind India's NCD programmes and the Ayushman Bharat health-and-wellness-centre model, where lifestyle-disease screening is a stated function. Finally, the science-and-technology framing — new drug classes, AI-enabled clinical decision systems, digital health — signals that the official narrative on obesity is moving from exhortation toward a technology-and-precision-medicine response, even as the front-line message remains lifestyle change: balanced diet, reduced oil, sustained discipline, adequate sleep and preventive care.

For Mains